What Is LDL Cholesterol and Why Is It Called “Bad”?

LDL cholesterol is the cholesterol carried through your bloodstream by low-density lipoprotein particles, and it earned the “bad” label because elevated levels drive plaque buildup inside artery walls. That said, “bad” is a simplification that obscures what LDL actually does, who it endangers most, and when the standard blood test number can be misleading. The biology is more layered than the nickname suggests, and some of the nuances matter for how you think about your own lab results.

What LDL Particles Actually Do

LDL particles are the main cholesterol delivery trucks in your blood. Their job is to carry cholesterol from the liver to cells throughout the body, where it is used for building cell membranes, making hormones, and other essential functions.¹ Cholesterol itself is not optional. Your cells need it to stay structurally intact, and certain tissues need it as the raw material for producing steroid hormones like cortisol, estrogen, and testosterone.² Without some LDL in circulation, those processes would stall.

So why the “bad” reputation? The trouble begins when there are more LDL particles in the blood than the body’s cells need. Under normal conditions, the liver pulls excess LDL back out of circulation using receptors on its surface. When those receptors are overwhelmed or underperforming, LDL particles linger in the bloodstream, and some of them begin infiltrating the walls of your arteries. That is where the damage starts.

How LDL Turns Dangerous Inside Artery Walls

When an LDL particle slips into the inner lining of an artery, it does not just sit there unchanged. The particle undergoes chemical modifications, with oxidation being the most important one.³ Oxidized LDL behaves very differently from normal LDL. It triggers inflammation and attracts immune cells called macrophages to the site.

Macrophages try to clean up the mess by engulfing the oxidized LDL. The problem is that macrophages are not built to handle large amounts of cholesterol. As they gorge on oxidized LDL, they balloon into what researchers call “foam cells,” which is an early and critical step in plaque formation.⁴ Unlike the normal receptor-based uptake of cholesterol (which has a built-in off switch when the cell has enough), the scavenger receptors that macrophages use to swallow oxidized LDL keep going without limit.⁵ The foam cells accumulate, die, and leave behind a core of fatty debris that forms the foundation of arterial plaque.

Over years and decades, these plaques grow, harden with calcium, and narrow the artery. In the worst case, a plaque ruptures, a blood clot forms on the spot, and a heart attack or stroke follows. This entire cascade, from LDL infiltration to plaque rupture, is called atherosclerosis, and it is why LDL cholesterol is so closely watched as a risk marker.

The Liver’s Cleanup System and Why It Matters

Your liver clears LDL from the blood using a specific surface receptor. When this receptor is abundant and working well, LDL particles get pulled out of circulation before they have a chance to accumulate in artery walls. Every major cholesterol-lowering drug approved to date works, one way or another, by increasing the number or availability of these receptors on liver cells.⁶

Statins, the most widely prescribed cholesterol drugs, reduce the liver’s own cholesterol production. When the liver makes less cholesterol internally, it compensates by putting more LDL receptors on its surface to grab cholesterol from the blood, which pulls LDL levels down.⁷ A newer class of drugs, PCSK9 inhibitors, takes a different approach. There is a protein called PCSK9 that normally tags LDL receptors for destruction inside liver cells. By blocking PCSK9, these drugs allow the receptors to be recycled back to the cell surface instead of being broken down, which means each liver cell can clear more LDL particles.⁸ Both strategies arrive at the same destination: fewer LDL particles circulating in the blood.

Not All LDL Particles Are the Same

When your doctor reports your LDL-C number, it measures the total amount of cholesterol riding inside LDL particles. But LDL particles come in a range of sizes and densities, and this variation may matter for heart risk. Smaller, denser LDL particles appear to differ from larger, more buoyant ones in how easily they penetrate artery walls and how readily they become oxidized.⁹ Two people with identical LDL-C numbers might carry very different mixes of these particle types, which could mean different levels of actual risk.

There is also a closely related particle called lipoprotein(a), or Lp(a), which is essentially an LDL particle with an extra protein attached. Lp(a) levels are largely genetic and do not respond much to diet or standard cholesterol drugs. A large genetic analysis estimated that Lp(a) is roughly six times more atherogenic than regular LDL on a per-particle basis.¹⁰ Most standard cholesterol panels do not measure Lp(a) separately, so someone with high Lp(a) could have misleadingly “normal” LDL-C results while carrying a hidden source of cardiovascular risk.

When Your LDL Number Can Mislead

The number on your lab report is usually calculated, not directly measured. The classic formula estimates LDL-C from your total cholesterol, HDL cholesterol, and triglycerides. This formula correlates well with direct measurement under typical conditions, but it becomes less accurate when triglycerides are high.¹¹

Beyond measurement quirks, there is a deeper issue. LDL-C tells you how much cholesterol is inside LDL particles but does not tell you how many particles you have. A metric called apolipoprotein B (apoB) counts the particles directly, since each LDL particle carries exactly one apoB molecule. Research increasingly suggests that apoB is the better predictor of cardiovascular risk. In a large study of young adults, people with high apoB but low LDL-C had significantly higher odds of developing coronary artery calcification than people whose LDL-C and apoB agreed.¹² The reverse was also true: high LDL-C with low apoB did not carry the same elevated risk. In other words, the particle count appeared to matter more than the cholesterol cargo.

This discordance between LDL-C and apoB is not rare. In a study of women, roughly one in five had meaningfully discordant levels, and for those women, relying on LDL-C alone underestimated or overestimated coronary risk by about 20 to 50 percent.¹³ A separate analysis of nearly 20,000 cardiovascular events found that after adjusting for apoB, neither LDL-C nor triglycerides added independent predictive value, while the reverse was not true: apoB remained a significant predictor even after accounting for LDL-C.¹⁴ Some cardiologists now argue that apoB should replace LDL-C as the primary target for treatment decisions, though guidelines have been slow to change.

Diet, Saturated Fat, and LDL

Diets high in saturated fat have long been linked to higher LDL cholesterol.¹⁵ The mechanism ties back to the liver’s cleanup system. Saturated fat appears to reduce the activity of LDL receptors on liver cells, which slows the clearance of LDL from the blood. With less LDL being pulled out of circulation, levels rise.¹⁶

That said, the relationship is not as simple as “eat less saturated fat, problem solved.” Individual responses to dietary saturated fat vary widely. Some people see large LDL increases on a high-saturated-fat diet; others see modest changes. The type of saturated fat matters too, since the saturated fats in dairy, meat, and coconut oil differ in their chemical structures and may not all affect LDL to the same degree. And as discussed above, the LDL-C number does not capture everything about particle composition. Still, the overall direction of the evidence is consistent: for most people, replacing a large share of saturated fat with unsaturated fat will lower LDL cholesterol.

Familial Hypercholesterolemia

Some people are dealt a genetic hand that makes high LDL essentially unavoidable from birth. Familial hypercholesterolemia (FH) is caused by mutations in the gene coding for the LDL receptor. When the receptor is defective, the liver cannot pull LDL out of the blood efficiently, and cholesterol levels soar. People with FH have dramatically elevated cardiovascular risk. In a large genetic screening study, FH patients had cardiovascular disease roughly 8.5 times more often than their unaffected relatives.¹⁷

The severity depends on the specific mutation. “Null” mutations, where the receptor does not function at all, produce higher LDL levels and worse outcomes than “defective” mutations, where the receptor works but poorly. In a study of over 800 FH patients, those with null mutations had significantly more premature cardiovascular disease.¹⁸ A follow-up analysis confirmed the pattern: after correcting for traditional risk factors, carrying a null mutation roughly doubled the hazard for major cardiovascular events compared to carrying a defective one.¹⁹ FH is probably the single strongest piece of evidence that LDL itself causes atherosclerosis, since these patients develop severe heart disease at young ages with no other obvious explanation.

What “Normal” LDL Looks Like in Evolutionary Context

Modern guidelines typically consider an LDL-C below 100 mg/dL “optimal” and treat anything above 130 mg/dL as elevated. But these thresholds are set relative to the populations we live in, not relative to human biology in its ancestral state. LDL levels in hunter-gatherer societies, healthy newborns, wild primates, and other free-living mammals cluster much lower, roughly in the range of 50 to 70 mg/dL, and none of these populations develop atherosclerosis.²⁰ Total cholesterol in recently studied hunter-gatherer populations tends to fall below 150 mg/dL, well below the 200 mg/dL threshold that modern medicine considers “desirable.”²¹

This context matters because it reframes what we consider “normal.” An LDL of 120 mg/dL might place you in a reassuring percentile on a chart calibrated to affluent Western adults, but it is still roughly double what human physiology seems to have been selected for. The atherosclerotic process is slow and cumulative, so even levels considered borderline by modern standards can contribute to plaque accumulation over a lifetime.

The Elderly LDL Paradox

One of the more puzzling findings in cholesterol research is that the tight link between high LDL-C and dying sooner appears to weaken, and sometimes even reverse, in people over 60. A systematic review of cohort studies in older adults found that in nearly 80 percent of the populations examined, higher LDL-C was actually associated with lower overall mortality.²² That is the opposite of what the “bad cholesterol” label would predict.

Before you throw away your statin prescription, there are important caveats. This paradox may reflect what epidemiologists call reverse causation: serious illnesses like cancer and chronic infections lower cholesterol levels as a side effect, so people with low LDL in old age may already be sick, dragging the averages down. A post hoc analysis of healthy older adults suggested that the paradox was concentrated among frail individuals and did not appear in those without frailty.²³ The paradox is real in the data, but it may tell us more about what happens to cholesterol when the body is declining than about whether LDL is suddenly protective.

Relative Risk Versus Absolute Risk

Part of the reason LDL’s “bad” reputation carries so much force in public messaging is the way risk reduction from treatment is typically communicated. Clinical trial results are often presented as relative risk reductions, which sound impressive. If a drug cuts heart attacks from two percent to one percent over five years, that is a 50 percent relative reduction. But the absolute reduction is one percentage point, meaning 100 people need to take the drug for five years to prevent one heart attack in one of them. A meta-analysis examining statin trials found that the absolute risk reductions for death, heart attack, and stroke were modest compared to the relative reductions, and that a clear connection between how much LDL-C dropped and how much absolute clinical benefit followed was not firmly established.²⁴

This does not mean LDL reduction is useless. For people at high baseline risk, including those with existing heart disease, diabetes, or very high LDL, the absolute benefit of treatment is larger because there is more risk to reduce. Where the critique has real bite is for people at low baseline cardiovascular risk, where the absolute benefit of aggressive LDL lowering can be genuinely small. Researchers have noted that relying on relative risk figures makes it easy for trial directors to present modest results as dramatic successes while sidelining the absolute numbers that patients would find more meaningful.²⁵ When you discuss your own numbers with a doctor, asking “what is my absolute risk reduction?” is a more useful question than “by what percentage does this lower my risk?”

HDL and LDL Are Not Simple Opposites

The labeling of LDL as “bad” and HDL as “good” makes for a tidy story, but the relationship between the two is more intertwined than the nicknames suggest. HDL particles are generally thought of as the trucks that haul excess cholesterol back from tissues to the liver for disposal, a process called reverse cholesterol transport. But research has shown that this pathway can actually involve LDL receptors on the liver, meaning that the same receptor system that clears LDL also participates in handling cholesterol delivered by HDL.²⁶ The two systems are not running in opposite directions so much as they are sharing infrastructure in complicated ways.

Efforts to raise HDL pharmacologically have mostly failed to reduce cardiovascular events, which has shaken confidence in the idea that HDL is straightforwardly “good.” The picture that has emerged over the past decade is that the number of apoB-containing particles circulating in your blood, the vast majority of which are LDL, is probably a better single marker of risk than either the LDL-C or HDL-C number in isolation. That does not make the “good” and “bad” labels completely wrong, but it does make them incomplete.

Newer Drug Approaches Beyond Statins

Although statins remain the backbone of LDL-lowering treatment, the toolkit has expanded. PCSK9 inhibitors (injectable antibodies given every two to four weeks) can cut LDL-C dramatically in people who do not reach target levels on statins alone or who cannot tolerate them. A newer option, inclisiran, uses a small interfering RNA molecule to silence the gene that produces PCSK9 in the liver, achieving similar LDL reductions with injections only twice a year after an initial loading dose.²⁷ Both approaches work by the same underlying logic as statins: get more LDL receptors functioning on liver cells so the blood is cleared of LDL particles more efficiently.²⁸

The development of drugs that target Lp(a) specifically is an active area of research, since current therapies do not meaningfully lower it. If those drugs succeed in clinical trials, the cholesterol conversation may shift further away from the single LDL-C number and toward a more granular accounting of which particles are in the blood and how many of them are there.